Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gaurav Rao

Interventional Cardiology Manhasset, NY Medical Doctor

NPI 1083957021 CMS profile 7233272

300 Community Dr, Unit 1D, Manhasset, NY 11030

Open in the dashboard

General payments

$32,759

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gaurav Rao of Manhasset, NY is reported in the CMS Open Payments database as having received $32,759 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,156 44
2024 General $4,585 30
2023 General $12,441 68
2022 General $5,228 48
2021 General $451 8
2020 General $1,650 17
2019 General $248 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gaurav Rao
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Gaurav Rao were reported at $8,156. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Gaurav Rao Interventional Cardiology median Middle half National median
2019 $248 $1,097 $329–$3,048 $163
2020 $1,650 $473 $161–$1,480 $114
2021 $451 $677 $233–$1,827 $132
2022 $5,228 $978 $333–$2,724 $149
2023 $12,441 $1,136 $382–$2,986 $160
2024 $4,585 $1,181 $395–$3,326 $164
2025 $8,156 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $7,705 77 payments
  2. ZOLL Circulation Inc $7,351 9 payments
  3. Medtronic, Inc. $6,185 37 payments
  4. Penumbra, Inc. $5,553 31 payments
  5. Inari Medical, Inc. $1,448 12 payments
  6. Edwards Lifesciences Corporation $1,376 11 payments
  7. Boston Scientific Corporation $618 10 payments
  8. Abiomed $557 5 payments
  9. Acist Medical Systems, Inc. $465 5 payments
  10. Philips Electronics North America Corporation $340 3 payments
  11. Other $1,160 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,464 40 payments
  2. Food and Beverage $12,257 171 payments
  3. Consulting Fee $5,538 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
Products named General payments · program years 2019–2025
  1. TherOx DS2 Console $7,351 9 payments
  2. Downstream Cartridge $7,351 9 payments
  3. Catheter $7,351 9 payments
  4. Indigo System $5,454 29 payments
  5. CARDIOMEMS $3,086 31 payments
  6. OPTIS $2,401 20 payments
  7. CT THROMBECTOMY SYSTEM KIT $1,292 11 payments
  8. FLOWTRIEVER CATHETER, S $1,292 11 payments
  9. MITRACLIP $886 9 payments
  10. SYMPLICITY G3 $592 10 payments
  11. Other $5,234 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

390

Median for Interventional Cardiology: 2,236

Drug cost

$58,533

Median for Interventional Cardiology: $380,412

Branded share of claims

23.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 12 $17,831
Farxiga Dapagliflozin Propanediol Brand 17 $17,217
Eliquis Apixaban Brand 15 $11,941
Repatha Syringe Evolocumab Brand 17 $9,611
Atorvastatin Calcium Generic 96 $606
Metoprolol Succinate Generic 65 $372
Losartan Potassium Generic 64 $258
Torsemide Generic 12 $252
Clopidogrel Clopidogrel Bisulfate Brand 29 $219
Carvedilol Generic 15 $89

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$196,980

Medicare's payments for the services billed

Medicare patients

395

Average age 77

Services billed

1,376

167 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 58%
Heart failure 47%
Diabetes 46%
Atrial fibrillation 41%
Chronic kidney disease 31%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $13
$13 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record